Microbicides 2002: an update.
Given that an acquired immune deficiency syndrome (AIDS) vaccine is more likely to mitigate than avert human immunodeficiency virus (HIV) infection, prevention efforts are focused on the development of a microbicide to reduce the sexual transmission of HIV. In this context, a microbicide might take the form of a cream or gel applied topically prior to sexual intercourse to lower the risk of HIV transmission. The most recent advances in the development of an anti-HIV microbicide were discussed at the International Microbicides 2002 Conference, held in Antwerp, Belgium, from May 12-15, 2002. Highlights from the conference, including basic scientific, clinical, and social, political and economic aspects of microbicide development, are presented here.
Johnston
Rowena
R
American Foundation for AIDS Research, New York, New York 10005, USA. Rowena.Johnston@amfar.org
D019380:Anti-HIV Agents; D001530:Belgium; D015658:HIV Infections / Q000517:prevention & control*; D006801:Humans; D015229:Sexually Transmitted Diseases, Viral / Q000517:prevention & control*
D019380:Anti-HIV Agents